IGF1 and esophageal squamous cell carcinoma: Importantly, IGF1R inhibitor Linstinib, Akt inhibitor MK‐2206, and mTOR inhibitor Rapamycin either alone or in combination attenuated the activation of IGF1R/Akt/mTOR/4E‐BP1/c‐Myc signaling axis and the upregulation of QSOX2 in ESCC cells induced by CAFs‐derived conditioned media or IGF‐1 recombinant protein (Figure 6F‐I; Figure S7C, Supporting Information).